# OnCo record nct04417621 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04417621/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04417621", "NCT04417621" ;
  schema:name "Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma"@en ;
  schema:description "A phase 2 trial of Naporafenib, Trametinib, Ribociclib in melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04417621/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04417621> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-10-30" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/naporafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/ribociclib/> ;
  onco:companies <https://onco.cc/companies/novartis/> .